As with many transformative efforts, we believe developing collaborations and partnerships is a key part of our strategy to successfully leverage our RTGel platform to enhance our product portfolio in uro-oncology and beyond.
We currently have an exclusive worldwide license agreement with Allergan to evaluate BotuGel™, proprietary RTGel-based formulation of BOTOX®* (onabotulinumtoxin A) in development for the treatment of overactive bladder (OAB), currently in a Phase 2 clinical trial.

Are you interested in partnering with UroGen?
Please contact us at

*BOTOX is a registered trademark of Allergan Pharmaceuticals


UroGen Pharma
499 Park Avenue, Suite 1200
NY 10022, U.S.A
+1-646-768-9780 ext 1001